AR128120A1 - Células t cd4⁺ de polidadores que expresan il-10 y sus usos - Google Patents

Células t cd4⁺ de polidadores que expresan il-10 y sus usos

Info

Publication number
AR128120A1
AR128120A1 ARP220103602A ARP220103602A AR128120A1 AR 128120 A1 AR128120 A1 AR 128120A1 AR P220103602 A ARP220103602 A AR P220103602A AR P220103602 A ARP220103602 A AR P220103602A AR 128120 A1 AR128120 A1 AR 128120A1
Authority
AR
Argentina
Prior art keywords
cells
polydator
cd4il
cell
methods
Prior art date
Application number
ARP220103602A
Other languages
English (en)
Inventor
Vries Jan Egbert De
Maria Grazia Roncarolo
Xavier Paliard
Vries David De
Original Assignee
Tr1X Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tr1X Inc filed Critical Tr1X Inc
Publication of AR128120A1 publication Critical patent/AR128120A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona una población de células CD4IL⁻¹⁰ de polidadores generadas al modificar genéticamente células T CD4⁺ de al menos dos dadores de células T diferentes. Además, se proporcionan métodos para generar las células CD4IL⁻¹⁰ de polidadores y métodos para utilizar las células CD4IL⁻¹⁰ de polidadores para la inmunotolerización, para tratar la GvHD, para trasplante de células y órganos, para el cáncer, para enfermedades autoinmunitarias e inflamatorias y para otros trastornos inmunitarios. Reivindicación 64: Una composición farmacéutica caracterizada porque comprende: (I) la población de células T CD4⁺ de una cualquiera de las reivindicaciones precedentes; en suspensión en (II) un vehículo farmacéuticamente aceptable.
ARP220103602A 2021-12-30 2022-12-27 Células t cd4⁺ de polidadores que expresan il-10 y sus usos AR128120A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163295389P 2021-12-30 2021-12-30

Publications (1)

Publication Number Publication Date
AR128120A1 true AR128120A1 (es) 2024-03-27

Family

ID=85157543

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103602A AR128120A1 (es) 2021-12-30 2022-12-27 Células t cd4⁺ de polidadores que expresan il-10 y sus usos

Country Status (6)

Country Link
EP (1) EP4457238A1 (es)
AR (1) AR128120A1 (es)
AU (1) AU2022423981A1 (es)
IL (1) IL313928A (es)
TW (1) TW202334399A (es)
WO (1) WO2023129922A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180050092A1 (en) 2015-03-13 2018-02-22 Fondazione Telethon Il-10-producing cd4+ t cells and uses thereof
WO2019002633A1 (en) * 2017-06-30 2019-01-03 Cellectis CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION
EP3980035A4 (en) * 2019-06-07 2023-08-23 The Board Of Trustees Of The Leland Stanford Junior University GENETICALLY MODIFIED CD4+ T LYMPHOCYTES FOR USE IN TREG-BASED IMMUNOTHERAPY
WO2022005462A1 (en) * 2020-06-30 2022-01-06 Tr1X, Inc. Poly-donor cd4+ t cells expressing il-10 and uses thereof

Also Published As

Publication number Publication date
WO2023129922A1 (en) 2023-07-06
EP4457238A1 (en) 2024-11-06
TW202334399A (zh) 2023-09-01
IL313928A (en) 2024-08-01
AU2022423981A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
Ruella et al. Next-generation chimeric antigen receptor T-cell therapy: going off the shelf
Wolf et al. Novel approaches to exploiting invariant NKT cells in cancer immunotherapy
Liu et al. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
Strzelec et al. Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system
Robinson et al. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide
Kleinman et al. Regulatory T cells as potential targets for HIV cure research
Lei et al. Mechanisms of immune tolerance in liver transplantation-crosstalk between alloreactive T cells and liver cells with therapeutic prospects
Tavasolian et al. The impact of immune cell-derived exosomes on immune response initiation and immune system function
CY1121857T1 (el) Ενωσεις οι οποιες επεκτεινουν αιμοποιητικα βλαστοκυτταρα
de Oliveira Bravo et al. Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression
Eggenhofer et al. Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts
Saito et al. Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1–specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature
Siatskas et al. A consensus statement addressing mesenchymal stem cell transplantation for multiple sclerosis: it’s time!
Haase et al. Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD
Fessler et al. Therapeutic potential of regulatory T cells in autoimmune disorders
Hall et al. Induction of antigen specific CD4+ CD25+ Foxp3+ T regulatory cells from naïve natural thymic derived T regulatory cells
AR128120A1 (es) Células t cd4⁺ de polidadores que expresan il-10 y sus usos
Pierini et al. Regulatory T cell immunotherapy in immune-mediated diseases
MX2023000202A (es) Celulas t cd4+ de poli-donadores que expresan il-10 y usos de las mismas.
Barrett et al. Prophylaxis of acute GVHD: manipulate the graft or the environment?
Wang et al. Research progress on regulatory T cells in acute kidney injury
CA3229529A1 (en) Lymphocyte population and methods for producing same
Szabolcs The immunobiology of cord blood transplantation
Tripathi et al. Adenosinergic pathway and linked suppression: two critical suppressive mechanisms of human donor antigen specific regulatory T cell lines expanded post transplant
Iwaszkiewicz-Grzes et al. Antigen-reactive regulatory T cells can be expanded in vitro with monocytes and anti-CD28 and anti-CD154 antibodies